Monopar Therapeutics Inc.
MNPR
$60.63
$0.020.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -14.99M | -13.72M | -19.44M | -17.31M | -16.57M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.66M | 4.00M | 8.44M | 7.54M | 6.59M |
| Change in Net Operating Assets | 1.31M | -2.49M | 175.90K | -40.30K | -432.80K |
| Cash from Operations | -10.01M | -12.20M | -10.83M | -9.81M | -10.41M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -68.71M | -63.45M | -15.60M | -12.49M | -13.68M |
| Cash from Investing | -68.71M | -63.45M | -15.60M | -12.49M | -13.68M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 127.78M | 127.79M | 184.00M | 56.22M | 56.22M |
| Repurchase of Common Stock | -36.29M | -36.22M | -35.90M | -536.10K | -224.50K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 91.49M | 91.57M | 148.10M | 55.69M | 55.99M |
| Foreign Exchange rate Adjustments | 65.70K | 97.20K | -6.10K | -2.00K | 2.10K |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | 0.00 | -- | -- |
| Net Change in Cash | 12.83M | 16.02M | 121.66M | 33.38M | 31.90M |